Pediatric Neurology
Volume 25, Issue 4 , Pages 325-327 , October 2001

Intravenous immunoglobulin for cranial polyneuropathy associated with Campylobacter jejuni infection

  • Hiroyuki Wakamoto, MD

      Affiliations

    • Corresponding Author InformationCommunications should be addressed to: Dr. Wakamoto; Department of Pediatrics; Ehime Prefecture Niihama Hospital; 3-1-1, Hongo, Niihama City; Ehime 792-0042, Japan
    • Department of Pediatrics, Ehime Prefecture Niihama Hospital, Ehime, Japan
    • ,
  • Masaaki Ohta, MD

      Affiliations

    • Department of Pediatrics, Ehime Prefecture Niihama Hospital, Ehime, Japan
    • ,
  • Naoko Nakano, MD

      Affiliations

    • Department of Pediatrics, Ehime Prefecture Niihama Hospital, Ehime, Japan
    • ,
  • Masahiko Tagawa, MD

      Affiliations

    • Department of Neurosurgery, Ehime Prefecture Niihama Hospital, Ehime, Japan
    • ,
  • Toshitaka Shiraishi, MD

      Affiliations

    • Department of Neurosurgery, Ehime Prefecture Niihama Hospital, Ehime, Japan

Received 3 January 2001 ,Accepted 2 May 2001.

References 

  1. Asbury AK. Diagnostic considerations in Guillain-Barré syndrome. Ann Neurol. 1981;9:1–5
  2. Hokkanen E, Haltia T, Myllylä VV. Recurrent multiple cranial neuropathy. Eur Neurol. 1978;17:32–37
  3. Juncos JL, Beal MF. Idiopathic cranial polyneuropathy. A fifteen-year experience. Brain. 1987;110:197–211
  4. Polo A, Manganotti P, Zanette G, De Grandis D. Polyneuritis cranialis (clinical and electrophysiological findings). J Neurol Neurosurg Psychiatry. 1992;55:398–400
  5. Matsubara K, Nigami H, Haragaya H, Baba K. Cranial polyneuropathy with elevated serum antiganglioside antibody. Pediatr Neurol. 1997;16:149–151
  6. Van der Meché FGA, Schmitz PIM. Dutch Guillain-Barré Study Group. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. N Engl J Med. 1992;326:1123–1129
  7. Hao Q, Saida T, Kuroki S, et al.  Antibodies to gangliosides and galactocerebroside in patients with Guillain-Barré syndrome with preceding Campylobacter jejuni and other identified infections. J Neuroimmunol. 1998;81:116–126
  8. Kuroki S, Saida T, Nukina M, et al.  Campylobacter jejuni strains from patients with Guillain-Barré syndrome belong mostly to Penner serotype 19 and contain β-N-acetylglucosamine residues. Ann Neurol. 1993;33:243–247
  9. Guillain-Barré Syndrome Steroid Trial Group . Double-blind trial of intravenous methylprednisolone in Guillain-Barré syndrome. Lancet. 1993;341:586–590
  10. Munsat TL, Barnes JE. Relation of multiple cranial dysfunction to the Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry. 1965;28:115–120
  11. Siedle PL, Knezevic WV, Bridge DT. Cerebral infarction complicating intravenous immunoglobulin therapy for polyneuritis cranialis. Neurology. 1992;42:257–258
  12. Ho TW, Hsieh ST, Nachamkin I, et al.  Motor nerve terminal degeneration provides a potential mechanism for rapid recovery in acute motor axonal neuropathy after Campylobacter infection. Neurology. 1997;48:717–724
  13. Yuki N, Takahashi M, Tagawa Y, Kashiwase K, Tadokoro K, Saito K. Association of Campylobacter jejuni serotype with antiganglioside antibody in Guillain-Barré syndrome and Fisher’s syndrome. Ann Neurol. 1997;42:28–33
  14. Yuki N, Yamada M, Sato S, et al.  Association of IgG anti-GD1a antibody with severe Guillain-Barré syndrome. Muscle Nerve. 1993;16:642–647
  15. Ho TW, Willison HJ, Nachamkin I, et al.  Anti-GD1a antibody is associated with axonal but not demyelinating forms of Guillain-Barré syndrome. Ann Neurol. 1999;45:168–173

PII: S0887-8994(01)00307-1

Pediatric Neurology
Volume 25, Issue 4 , Pages 325-327 , October 2001

Article Tools